General - Press Releases

Date	Title	Company
11-Dec-2023	Synchron Appoints Andy Rasdal to Board of Directors	Businesswire
11-Dec-2023	Shape Memory Medical Announces Sublicense of Intellectual Property	Businesswire
11-Dec-2023	Thermo Fisher Scientific Introduces New Sample Preparation Solutions to Simplify and Automate Respiratory Diagnostic Testing	Businesswire
11-Dec-2023	Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	Businesswire
11-Dec-2023	Takara Bio USA Wins EU Opposition Hearing, Revoking Jumpcode Genomics’ NGS Library Enrichment Patent	Businesswire
11-Dec-2023	United States Syringes & Needles Market Insights Report 2023: A $10.87 Billion Market by 2028 with BD, ICU Medical, Nipro Medical, Terumo, and Cardinal Health Emerging as Prominent Players - ResearchAndMarkets.com	Businesswire
11-Dec-2023	First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)	Businesswire
11-Dec-2023	Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)	Businesswire
11-Dec-2023	Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer	Businesswire
11-Dec-2023	Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs	Businesswire
11-Dec-2023	Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer	Businesswire
11-Dec-2023	Cytovance Biologics and Alcami Unite to Deliver End-to-End Solutions for Biologics Developers	Businesswire
11-Dec-2023	DeepMirror Launches Early Access Programme for Its Intuitive Molecular Drug Design Software	Businesswire
11-Dec-2023	RWS awarded silver medal by EcoVadis for sustainability achievements	Businesswire
11-Dec-2023	MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023	Businesswire
11-Dec-2023	OSE Immunotherapeutics and Nantes University Hospital Present Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant	Businesswire
11-Dec-2023	Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023	Businesswire
11-Dec-2023	ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023	ImmunOs Therapeutics
11-Dec-2023	Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia	Businesswire
11-Dec-2023	ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma	Businesswire